IDEX Corporation delivered record results for the third quarter of 2026, exceeding analyst expectations for both sales and earnings. Performance was anchored by significant growth in the Health & Science Technologies segment and robust order intake across the portfolio, leading the company to raise its full-year 2026 financial guidance for organic sales and adjusted EPS.
Key Highlights
- Record sales of $951.7 million increased 8% year-over-year, driven by organic volume growth and favorable pricing.
- Total orders reached $991.2 million, a 13% increase over the prior year, reflecting broadening momentum across all reporting segments.
- Health & Science Technologies (HST) revenue surged 14% to $433.5 million, primarily supported by AI-driven demand for data center power and semiconductor markets.
- Adjusted gross margin expanded 70 basis points to 45.2%, as the company successfully leveraged higher volumes and productivity improvements to offset inflationary headwinds.
- Management raised FY2026 organic sales guidance to a range of 6.5% to 6.8% and adjusted diluted EPS guidance to $8.91 to $8.96.